TBP AUDIO FILES
AI-generated audio files
TBP AUDIO FILES
Long-Term Follow-Up and Reassessment in von Willebrand Disease
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Imagine um for just a second that you've been searching for a medical diagnosis for years.
SPEAKER_02Yeah, which is an exhausting process.
SPEAKER_01Oh, completely. Like something has been wrong, you've seen doctor after doctor run, you know, test after test, and finally you get it. You get the actual name, the condition.
SPEAKER_02Right, the golden ticket.
SPEAKER_01Exactly. And usually when we talk about getting a medical diagnosis, there is this, I mean, this underlying expectation of absolute precision. It feels like crossing a finish line.
SPEAKER_02Oh, for sure.
SPEAKER_01Think about it like structural engineering. You know, you fall, your arm hurts, you get an X-ray, and it shows a jagged white line across the bone.
SPEAKER_02Right. There's the proof. Aaron Powell Yeah.
SPEAKER_01The doctor just points at the screen and says, there it is. The mystery is completely solved.
SPEAKER_02Aaron Powell Right. I mean, it is incredibly comforting because human beings, we just love to categorize things.
SPEAKER_01We really do.
SPEAKER_02We have this deep psychological need to put our problems into like neat labeled boxes. And once that label is applied, we tend to view that diagnosis as well, the end of the investigative story.
SPEAKER_01Aaron Powell But today, we're actually completely flipping that assumption upside down. We are going on a deep dive to explore why a medical diagnosis is well why it's actually never the end of the story.
SPEAKER_02It's really just the beginning.
SPEAKER_01Exactly. It is just the starting line of a lifelong, like constantly evolving relationship with your own biology.
SPEAKER_02Yeah, it's so dynamic.
SPEAKER_01Aaron Powell And we are pulling from a really fascinating stack of medical literature today, kind of anchoring our discussion on this brilliant clinical framework. It's laid out in a paper by William Ayrd titled Long-Term Follow-up and Reassessment in Von Willebrand Disease.
SPEAKER_02Aaron Powell Which is just a remarkable piece of literature, honestly.
SPEAKER_01It really is.
SPEAKER_02It provides this incredibly robust clinical framework, complete with some really eye-opening case studies. And it details how doctors actually have to track this specific inherited bleeding disorder over a patient's entire lifespan.
SPEAKER_01And look, even if you do not have a bleeding disorder, you absolutely need to hear this.
SPEAKER_02Oh, 100%. The principles apply to everyone.
SPEAKER_01Right. So we are going to explore the mechanics of von Willebrand disease, or VWD for short. But more importantly, you are going to walk away with a powerful new framework for thinking about your own health and, you know, longevity.
SPEAKER_02Aaron Powell Because you'll see firsthand why a static label sitting in your medical chart simply can't, I mean, you just cannot account for the messy changing reality of human aging.
SPEAKER_01Aaron Powell Yeah. And if we pull back and look at the bigger picture, the core thesis embedded in this literature, it really challenges that traditional static view of healthcare. Trevor Burrus, Jr.
SPEAKER_02It totally disrupts it.
SPEAKER_01The foundational idea here is that in medicine, time itself is actually a diagnostic test.
SPEAKER_02Aaron Powell Time itself is a diagnostic test. I just I absolutely love that phrasing. Trevor Burrus, Jr.
SPEAKER_01It's so good. Right. So let's start by dismantling this entrenched idea that an inherited, you know, genetic condition is somehow just biologically frozen in time. Right. Because when a patient gets that initial VWD diagnosis, it feels so definitive. Their lifelong history of unexplained bruising or bleeding finally makes sense. Their labs are categorized. A specific subtype of the disease is put in their chart.
SPEAKER_02Aaron Powell And everyone just breathes a massive sigh of relief.
SPEAKER_00Exactly. The case is closed.
SPEAKER_02But to understand why that feeling of finality is, well, an illusion, we should probably look at what von Willebrand disease actually is at a biological level.
SPEAKER_01Aaron Powell Okay, let's break it down.
SPEAKER_02So von Willebrand factor is the specific protein circulating in your blood. If you get a cut, you can think of this protein as um like a specialized molecular glue.
SPEAKER_00Molecular glue, I like that.
SPEAKER_02Right. Its primary job is to help your blood platelets stick together and adhere to the wall of the injured blood vessel to form a clot.
SPEAKER_00Okay. Makes sense.
SPEAKER_02And if you have type one VWD, which is by far the most common form, your body simply does not produce enough of this glue.
SPEAKER_00Aaron Powell So it's a supply issue.
SPEAKER_02Exactly. So when that diagnosis is made, the doctor is basically identifying a deficiency. But that very first consultation is honestly, it's nothing more than a snapshot.
SPEAKER_00Right.
SPEAKER_02It's like a biological Polaroid of the patient's bleeding history and their laboratory values that just happen to be available on that one specific Tuesday in their life.
SPEAKER_01Let me see if I can put this into like a real world perspective. It sounds like buying a car based solely on a glossy photo in the dealership brochure versus actually driving that car on the highway, you know, through the snow over 10 years of commuting.
SPEAKER_02Yes, that is a perfect analogy.
SPEAKER_01Because the dealership photo tells you what the car is supposed to be, but the daily driving is what actually tells you how the engine holds up under pressure.
SPEAKER_02And that daily driving is what clinicians refer to as hemostatic challenges.
SPEAKER_01Hemostatic challenges.
SPEAKER_02Right. Because life is incredibly messy and it's full of these challenges. I mean, a a patient might go years without an issue, and then suddenly they need a complex dental extraction.
SPEAKER_00Oh, sure.
SPEAKER_02Or they experience severe physical trauma in a car accident. They might go through the uh the intense physiological stress of childbirth or need a major abdominal surgery.
SPEAKER_01And every single one of those events is basically a stress test.
SPEAKER_02Exactly. A massive stress test on the body's ability to clot blood.
SPEAKER_01Because the doctor couldn't possibly know how that patient's body would react to, say, the trauma of childbirth until it actually happens.
SPEAKER_02Aaron Ross Powell That have no way of knowing. The system is being tested under entirely new, extreme conditions.
SPEAKER_00Wow.
SPEAKER_02And each of those events generates brand new clinical data that was, well, it was completely unavailable during that initial snapshot assessment.
SPEAKER_01Aaron Powell So because a diagnosis is this living thing, doctors need a systematic way to track how your, you know, your car is performing over the decades.
SPEAKER_02Aaron Ross Powell Right. And to do that, they focus heavily on the patient's lived experience, which in medical terms is called their bleeding phenotype.
SPEAKER_01Aaron Powell I want to dig into that because the source material points out that tracking this live experience is wildly counterintuitive.
SPEAKER_02Oh, totally.
SPEAKER_01It isn't just a doctor asking, hey, did you bleed this year? It is a much deeper investigation into whether the actual burden or like the pattern of the bleeding has fundamentally shifted.
SPEAKER_02Yes. They're looking for new variables.
SPEAKER_01Aaron Powell Like have they started experiencing gastrointestinal bleeding, which was never part of their profile before? Or are they suddenly getting bleeding into their joint spaces?
SPEAKER_02Aaron Ross Powell Exactly. The clinical focus actively shifts away from those isolated static laboratory numbers, and it leans heavily into the real-world evidence.
SPEAKER_01Aaron Powell Because the lab numbers don't tell the whole story?
SPEAKER_02Not at all. A lab value just describes a microscopic fraction of a second in a vial of blood. But a longitudinal history records what actually happened when the rubber met the road.
SPEAKER_00Right.
SPEAKER_02And one of the most critical objective markers doctors look for in this lived experience is iron deficiency.
SPEAKER_01Aaron Powell Which is fascinating because I think most of us view iron deficiency as just, I don't know, a minor random lab abnormality. Trevor Burrus, Jr.
SPEAKER_02Oh, a lot of people do. Like it's no big deal. Trevor Burrus, Jr.
SPEAKER_01Right. You feel a little tired, your doctor tells you to eat more spinach or take a supplement and you just move on. But the literature highlights it as an undeniable marker of cumulative hidden blood loss.
SPEAKER_02Aaron Powell It is a massive red flag.
SPEAKER_01Aaron Powell So how does that actually work?
SPEAKER_02It really comes down to supply and demand in the bone marrow. Iron is a crucial building block for hemoglobin, which is the protein in your red blood cells that carries oxygen. So if a patient is slowly losing blood over time, say through really heavy menstrual periods, or a slow leak in the gastrointestinal tract, they are losing red blood cells faster than their body can absorb iron from their diet to replace them.
SPEAKER_01Wow. So the bone marrow literally gets starved of building blocks.
SPEAKER_02Exactly. So even if the patient is not actively reporting major dramatic bleeding events to their doctor, a chronic iron deficiency tells a completely different objective story.
SPEAKER_01It's basically the check engine light.
SPEAKER_02Yes. It reveals a slow, steady, cumulative burden.
SPEAKER_01And the burden isn't always physical either, right? I mean, the psychological toll is a massive part of that lived experience. It's huge. Sometimes the chronic anxiety about a potential bleeding episode becomes far more limiting for the patient than the actual bleeding itself.
SPEAKER_02It can be totally paralyzing.
SPEAKER_01Like the sheer fear of a joint bleed or a severe nosebleed stops them from traveling, from exercising, or from just living their daily lives.
SPEAKER_02And doctors have to factor that in.
SPEAKER_01Okay, hold on though. I'm genuinely confused by something here. Let's play devil's advocate. Let's say a patient comes in, their iron is crashing, their anxiety is through the roof, and their lived experience clearly shows they are bleeding more than they used to.
SPEAKER_02Okay, a worsening phenotype.
SPEAKER_01Right. The solution seems incredibly obvious to me. Shouldn't the doctor just double their VWD clotting medication, give them some iron, and send them home? Like, why is this such a complex puzzle?
SPEAKER_02Well, that is the exact trap doctors have to aggressively avoid falling into.
SPEAKER_00Really? Why?
SPEAKER_02Because if a clinician just instinctively increases the VWD treatment without asking why the patient is bleeding more, they might cause serious harm.
SPEAKER_00Okay, now I'm intrigued.
SPEAKER_02And this brings us to the most surprising paradox in chronic care, honestly. An increase in symptoms does not automatically mean the underlying inherited disease is getting worse.
SPEAKER_00Wait, what?
SPEAKER_02Yeah. Biology and bleeding simply do not always move in the same direction.
SPEAKER_01Okay, you have to explain that. How can the bleeding get worse if the genetic disease itself isn't getting worse?
SPEAKER_02It has to do with how dynamic the human body is, specifically the von Willebrand factor protein itself.
SPEAKER_01The molecular glue.
SPEAKER_02Exactly. It is not a static number etched in stone. The levels of this protein fluctuate wildly based on environmental and physiological factors.
SPEAKER_00Like what kind of factors?
SPEAKER_02Well, if a patient is pregnant, their levels skyrocket. If they have an acute illness or systemic inflammation, or even if they are under immense physical stress, the body attempts to pump out more of this protein.
SPEAKER_00Okay, so it reacts to stress.
SPEAKER_02Yes. But the most significant variable of all, the one that changes everything, is aging.
SPEAKER_01So aging actually changes the amount of this glue in the blood.
SPEAKER_02Dramatically. The paper references some incredible observational cohort data published in 2024 by a researcher named Atik and colleagues.
SPEAKER_00Okay, what did they find?
SPEAKER_02They tracked patients with type 1 VWD over a really long period, and they found that as these patients got older, a significant portion of them, about 23%, saw their von Willebrand factor levels naturally rise so much that they completely crossed over into the normal, healthy range.
SPEAKER_01Oh wow. So looking purely at the lab sheet, those patients are essentially cured. I mean, they have enough glue to form a clot now.
SPEAKER_02Right. On paper, their lab numbers are indistinguishable from someone without a bleeding disorder.
SPEAKER_01That's amazing.
SPEAKER_02But here's the massive paradox that keeps hematologists up at night. Even though their laboratory levels normalized, their bleeding phenotype, you know, their actual day-to-day lived experience of bleeding remained largely the same.
SPEAKER_00Wait, really?
SPEAKER_02Yeah. They were still suffering from bleeding issues as if their protein levels were completely bottomed out.
SPEAKER_01But logically, how is that even possible? If the very protein designed to stop the blooding has returned to normal levels, why is the bleeding still happening?
SPEAKER_02Well, that is a biological enigma that researchers are still trying to fully unravel. But the prevailing theory is basically twofold.
SPEAKER_00Okay.
SPEAKER_02First, the extra von Willebrand factor that the aging body desperately produces, it might actually be dysfunctional. It's like a factory rushing to meet a quota. They're pumping out a lot of product, but the quality control is terrible, so the glue just isn't sticky enough.
SPEAKER_01Quality over quantity. That makes sense. What's the second part?
SPEAKER_02Second, you have to consider the blood vessels themselves. Decades of microbleeding, aging, and subtle wear and tear can cause structural changes in the endothelium, the lining of the blood vessels.
SPEAKER_01The pipes themselves get old.
SPEAKER_02Exactly. The pipes themselves become fragile. So even with a normal amount of glue, the fragile pipes still leak.
SPEAKER_01Which means the diagnosis is infinitely more complicated than just checking a box on a lab sheet.
SPEAKER_02Completely. And because of this exact paradox, the 2021 diagnostic guidelines from major hematology organizations introduced this really crucial nuance.
SPEAKER_01What did they change?
SPEAKER_02They suggest that doctors should reconsider a type 1 VWD diagnosis when a patient's levels normalize with age. But they explicitly warn doctors not to automatically erase the diagnosis from the chart.
SPEAKER_01Well, yeah, because reconsidering is fundamentally different than erasing. Erasing it completely wipes out decades of historical context.
SPEAKER_02Aaron Powell Right. And that context is a matter of life and death, honestly, because this biological paradox actually swings in both directions.
SPEAKER_01What do you mean?
SPEAKER_02Well, we just explored how lab levels can look perfectly normal while the bleeding continues, right?
SPEAKER_00Yeah.
SPEAKER_02Conversely, a patient's bleeding can suddenly become dangerously severe while their underlying von Willebrand factor levels remain perfectly stable.
SPEAKER_01Right. And I assume that happens because of entirely new, like unrelated variables entering the picture as the patient ages.
SPEAKER_02Exactly. New variables change everything.
SPEAKER_01Like if you hit 65 and your cardiologist puts you on strong antiplatelet drugs or blood thinners for a heart condition, you are obviously going to bleed more.
SPEAKER_02For sure.
SPEAKER_01But it has absolutely nothing to do with your genetic VWD getting more severe. Or actually, the literature mentions structural gut issues like angiodysplasia.
SPEAKER_02Yes, angiodisplasia is a perfect example of the put that down for me. So as we age, the blood vessels in the gastrointestinal tract can become dilated, torturous, and just incredibly thin-walled. They look almost like tangled spider wings in the gut.
SPEAKER_00Oh, that doesn't sound good.
SPEAKER_02No, they are incredibly prone to rupturing. So if a VWD patient develops these, their bleeding will skyrocket. But treating the Von Willebrand disease won't fix the anatomical problem in the gut.
SPEAKER_01Okay, this is slowly clicking for me.
SPEAKER_02Yeah.
SPEAKER_01It's like driving down the highway and suddenly the fuel gauge on your dashboard shoots up to full. Just because the car got older, but the engine is still sputtering and acting like it's running on empty.
SPEAKER_02That's it, exactly.
SPEAKER_01You can't just blindly trust the beige anymore. And you certainly can't just pour more gas into the tank. You have to pull over, pop the hood, and look at the entire complex system to figure out why the car is actually stalling.
SPEAKER_02That is a phenomenal way to visualize it. The established diagnosis from 20 years ago is just the starting point for medical reasoning.
SPEAKER_01Aaron Powell It's not the answer key.
SPEAKER_02Right. It is not a blanket, lazy explanation for every single symptom that patient experiences for the rest of their life.
SPEAKER_01Aaron Powell But this puts both the doctor and the patient in an incredibly difficult position, doesn't it?
SPEAKER_02It's incredibly tricky.
SPEAKER_01Because if the lab numbers are changing on their own and the actual bleeding patterns are changing completely independently of those lab numbers, how on earth do they decide what to actually do? How does the treatment adapt to a body that refuses to stay still?
SPEAKER_02Aaron Powell Well, that is where the practical reality of aging forces a complete shift in strategy. You simply cannot use a single lifelong treatment template.
SPEAKER_01Right. You can't just set it and forget it.
SPEAKER_02Exactly. A medication that worked beautifully when a patient was a healthy 20-year-old could easily become ineffective or even lethal when that same patient is 65. Lethal. Yeah. There is a common VWD treatment that perfectly illustrates this: a medication called desmopressin.
SPEAKER_01Oh, I saw that in the sources. How does that drug actually work?
SPEAKER_02So desmopressin is a synthetic hormone. And in a younger patient, it works brilliantly. It essentially acts like a sponge.
SPEAKER_01A sponge, okay, in what way?
SPEAKER_02It squeezes the endothelial cells that line the blood vessels and forces them to aggressively dump all their stored up von Willebrand factor directly into the bloodstream.
SPEAKER_01Oh wow. So it provides a massive, rapid boost of clotting power.
SPEAKER_02Exactly. It's incredibly effective.
SPEAKER_01Sounds like a silver bullet for a bleeding disorder.
SPEAKER_02It is, until it isn't. Because desmopressin has a potent secondary mechanism. It acts as an antidiuretic.
SPEAKER_01Which means it stops you from peeing.
SPEAKER_02Right. It sends a powerful signal to the kidneys telling them to stop producing urine and to hold on to water. Now, a 20-year-old's kidneys can usually handle that temporary water retention. Sure. But in a much older patient, holding on to all that excess water dramatically dilutes the sodium levels in their blood.
SPEAKER_01Oh, it's dangerous.
SPEAKER_02Very. This leads to a condition called hyponatremia, which can cause severe neurological issues, brain swelling, and even seizures. Furthermore, the drug can cause fluctuations in blood pressure, which is highly dangerous for an older patient who has already developed cardiovascular disease.
SPEAKER_01Wow. So the silver bullet literally transforms into a major risk factor purely because the biological landscape of the patient has aged.
SPEAKER_02It totally changes the risk profile. And this leads us directly to one of the most compelling case studies in the paper.
SPEAKER_00Oh, perfect.
SPEAKER_02It synthesizes every single thing we've discussed about the collision between inherited disease, aging, and changing risks.
SPEAKER_00Oh, I was hoping we would get to the case studies. Please walk me through this one.
SPEAKER_02Okay, so imagine a 19-year-old woman sitting in a doctor's office. She has a documented history of severe nosebleeds, debilitatingly heavy menstrual bleeding, and she is profoundly iron deficient.
SPEAKER_00Okay.
SPEAKER_02The doctor runs the labs, and her von Willebrand factor activity is critically low registering at just 28 international units per deciliter. Anything under 30 is a definitive flag. She is formally diagnosed with type 1 VWD.
SPEAKER_01Okay, so that is our classic, clear-cut initial snapshot. The mystery is solved for the teenager.
SPEAKER_02Now we fast forward to tape four decades. That same woman is now 62 years old. Okay. Because of the natural biological changes of aging we discussed earlier, her von Willebrand factor activity has naturally climbed all the way up to 74 international units.
SPEAKER_01Which is perfectly normal, right.
SPEAKER_02Perfectly indisputably normal. And she has also gone through menopause, so the heavy menstrual bleeding is completely gone.
SPEAKER_01So the original problems are technically resolved.
SPEAKER_02Right. But new problems have taken their place. She has developed atrial fibrillation. Her heart is beating irregularly, which means blood is pooling in the chambers of her heart. That pooling blood can easily form a clot, travel to her brain, and cause a massive fatal stroke.
SPEAKER_00Oh, wow.
SPEAKER_02To prevent this, her cardiologist says she absolutely must be put on powerful anticoagulant blood thinners.
SPEAKER_01Okay, but she has a bleeding disorder.
SPEAKER_02Exactly. And to make the puzzle even more complex, she's also experiencing recurrent gastrointestinal bleeding from those fragile, aging blood vessels in her gut we talked about.
SPEAKER_01Wait, I need to process this. You are saying a patient with a lifelong genetically documented bleeding disorder who is actively bleeding into her own gut is suddenly being prescribed a medication explicitly designed to make her bleed more.
SPEAKER_02Yes.
SPEAKER_01How does a doctor even begin to balance that kind of contradiction?
SPEAKER_02That is the ultimate tightrope walk of longitudinal care. The clinical scenario has entirely transformed.
SPEAKER_01It's completely upside down.
SPEAKER_02Did her genetic von Willebrand disease disappear? Well, her lab work says yes, but her history and her fragile blood vessels say no.
SPEAKER_00Right.
SPEAKER_02The doctors are no longer trying to manage heavy periods in a teenager. They are now forced to balance the very real, immediate risk of her bleeding internally in her gut against the absolute non-negotiable necessity of protecting her from a preventable stroke.
SPEAKER_01It is a complete paradigm shift. The diagnosis hasn't just evolved, it has effectively inverted upon itself. It really has. And the source material highlights that the latest guidelines, specifically the 2024 guidelines from the British Society for Hematology, are pushing hard for this kind of critical, targeted reassessment.
SPEAKER_02They are. They really want to change the standard of care.
SPEAKER_01Right. They are begging doctors to stop just checking boxes on a formulaic yearly schedule. They argue that laboratory testing should only be done to serve a specific clinical purpose, to answer a specific biological question about the patient's current state, not just to mindlessly log if a number went up or down.
SPEAKER_02Because treating the number on the paper instead of the complex aging human sitting in the room is how catastrophic medical errors happen.
SPEAKER_01So synthesizing all of this, what does this actually mean for the patient sitting on the exam table today?
SPEAKER_02That's the big question.
SPEAKER_01If the goal with aging isn't to magically achieve zero bleeding risk anymore, because that's obviously impossible, how do doctors and patients define the actual finish line?
SPEAKER_02Well, the profound realization of longitudinal care is that there is no final finish line.
SPEAKER_01None at all.
SPEAKER_02No, there is no ultimate cure. The new goal is achieving the best possible real-time balance between competing risks.
SPEAKER_01It's a negotiation.
SPEAKER_02Exactly. It is an ongoing, highly individualized negotiation with the patient's aging body. It requires constantly asking what is fundamentally changed in their lived experience? What actual biological mechanism explains that change, knowing that the lab numbers might be lying to us? And finally, how must we drastically alter the treatment plan to survive this new reality?
SPEAKER_01Wow. So that initial assessment you receive, that moment of relief when a doctor points to the metaphorical x-ray and gives your suffering a name is just establishing a working theory.
SPEAKER_02That's all it is.
SPEAKER_01It is the passage of time, the lived experience of hemostatic challenges, and the constantly shifting context of your aging body that actually refines the truth.
SPEAKER_02And we have to completely abandon the comfort of that binary mindset. You know, the idea of being simply broken or not broken might work for a fractured bone, but it completely fails us when managing the complexity of a human lifespan.
SPEAKER_01Aaron Powell Which brings us right back to you, the listener, because this deep dive into a specific genetic bleeding disorder is actually a universal masterclass in healthcare advocacy.
SPEAKER_02It really is.
SPEAKER_01It is absolute proof that you are not a static medical label written down in a chart a decade ago. You are a highly dynamic, constantly adapting biological system interacting with time.
SPEAKER_00Absolutely.
SPEAKER_01The body you inhabit at 20 is fundamentally different from your body at 40, 60, or 80, and you must demand that your medical care respects and adapts to that relentless evolution.
SPEAKER_02Because the picture of your health will inevitably change. And if the picture changes, the perspective of the person treating you must change right alongside it.
SPEAKER_01Which leaves us with a final slightly provocative thought for you to mull over as you go about your day. Well, I like this. If a diagnostic label from our youth, something as seemingly biological, genetic, and fixed as a bleeding disorder, can completely transform in its meaning as our biology and environment change over the decades, what other static labels sitting in our medical records or perhaps even in our psychological profiles might actually be holding us back from getting the care or making the necessary changes we so desperately need right now?